港股异动 | 昭衍新药(06127)跌超6%领跌CRO概念美联储加息可能性仍存国内创新药仍处调整周期

智通财经04-16

智通财经APP获悉，CRO概念股继续走低，截至发稿，昭衍新药(06127)跌5.98%，报9.28港元；泰格医药(03347)跌5.93%，报30.15港元；康龙化成(03759)跌5.18%，报8.78港元；药明康德(02359)跌3.96%，报32.75港元。消息面上，瑞银策略师表示，顽固的通胀和经济强劲增长提高了美联储加息而不是降息的可能性，明年利率最高可能升至6.5%。此外，近日有媒体报道...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2427818909?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-16 14:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2427818909","market":"us","top_or_hot":-1,"title":"港股异动 | 昭衍新药(06127)跌超6%领跌CRO概念 美联储加息可能性仍存 国内创新药仍处调整周期","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，CRO概念股继续走低，截至发稿，昭衍新药(06127)跌5.98%，报9.28港元；泰格医药(03347)跌5.93%，报30.15港元；康龙化成(03759)跌5.18%，报8.78港元；药明康德(02359)跌3.96%，报32.75港元。消息面上，瑞银策略师表示，顽固的通胀和经济强劲增长提高了美联储加息而不是降息的可能性，明年利率最高可能升至6.5%。此外，近日有媒体报道...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1103172.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 昭衍新药(06127)跌超6%领跌CRO概念 美联储加息可能性仍存 国内创新药仍处调整周期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 昭衍新药(06127)跌超6%领跌CRO概念 美联储加息可能性仍存 国内创新药仍处调整周期\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-16 14:37 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1103172.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，CRO概念股继续走低，截至发稿，昭衍新药(06127)跌5.98%，报9.28港元；泰格医药(03347)跌5.93%，报30.15港元；康龙化成(03759)跌5.18%，报8.78港元；药明康德(02359)跌3.96%，报32.75港元。消息面上，瑞银策略师表示，顽固的通胀和经济强劲增长提高了美联储加息而不是降息的可能性，明年利率最高可能升至6.5%。此外，近日有媒体报道...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1103172.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1103172.html","article_id":"2427818909","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2427818909","pubTimestamp":1713249456,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，CRO概念股继续走低，截至发稿，昭衍新药跌5.98%，报9.28港元；泰格医药跌5.93%，报30.15港元；康龙化成跌5.18%，报8.78港元；药明康德跌3.96%，报32.75港元。消息面上，瑞银策略师表示，顽固的通胀和经济强劲增长提高了美联储加息而不是降息的可能性，明年利率最高可能升至6.5%。此外，近日有媒体报道，美国生物安全法案所覆盖的企业名单可能会覆盖更多的中国CRO/CDMO企业。该行认为，海外需求将先于本土需求改善。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK1574":"生物医药B类股","OEF":"标普100指数ETF-iShares","YINN":"三倍做多富时中国ETF-Direxion","BK1583":"高瓴概念","LU1046422090.SGD":"Fidelity Pacific A-SGD","03347":"泰格医药","07226":"XL二南方恒科","02359":"药明康德","BK4559":"巴菲特持仓","SSO":"两倍做多标普500ETF","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","BK4588":"碎股","IVV":"标普500指数ETF","06127":"昭衍新药","BK4550":"红杉资本持仓","SDS":"两倍做空标普500ETF","SH":"标普500反向ETF","BK1161":"生物科技","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK4504":"桥水持仓","BK4581":"高盛持仓","SPXU":"三倍做空标普500ETF","YANG":"三倍做空富时中国ETF-Direxion","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","03759":"康龙化成","UPRO":"三倍做多标普500ETF","BK1141":"生命科学工具和服务","SPY":"标普500ETF","BK1576":"医药外包概念","06978":"永泰生物-B",".SPX":"S&P 500 Index","LU0052750758.USD":"富兰克林中国基金A Acc","OEX":"标普100","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD"},"translate_title":"Hong Kong stocks changed Zhaoyan New Drug (06127) fell more than 6%, leading the decline in CRO concept, the possibility of Fed rate hike still exists, domestic innovative drugs are still in the adjustment cycle","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"YINN":1,"YANG":1,"SPY":1,"06127":1,"06978":1,"07226":1,"02359":0.9,"03347":0.9,"03759":0.9,".SPX":0.6,"UPRO":0.6,"SSO":0.6,"SPXU":0.6,"SH":0.6,"SDS":0.6,"OEX":0.6,"OEF":0.6,"IVV":0.6,"ESmain":0.6},"content_text":"智通财经APP获悉，CRO概念股继续走低，截至发稿，昭衍新药(06127)跌5.98%，报9.28港元；泰格医药(03347)跌5.93%，报30.15港元；康龙化成(03759)跌5.18%，报8.78港元；药明康德(02359)跌3.96%，报32.75港元。消息面上，瑞银策略师表示，顽固的通胀和经济强劲增长提高了美联储加息而不是降息的可能性，明年利率最高可能升至6.5%。此外，近日有媒体报道，美国生物安全法案所覆盖的企业名单可能会覆盖更多的中国CRO/CDMO企业。太平洋证券指出，国内创新药仍处调整周期，需求不振，未来从投融资到需求、订单以及业绩的好转仍需时间；创新药CXO表现不佳，整体处于行业周期底部，预计2023业绩增速仅为2.76%，未来从需求的恢复到订单的落地、业绩的改善仍需一定时间；仿制药CXO等细分领域表现亮眼，预计业绩以及订单维持30%的高增速。该行认为，海外需求将先于本土需求改善。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2427818909"}

港股异动 | 昭衍新药(06127)跌超6%领跌CRO概念 美联储加息可能性仍存 国内创新药仍处调整周期

精彩评论

港股异动 | 昭衍新药(06127)跌超6%领跌CRO概念美联储加息可能性仍存国内创新药仍处调整周期